Form 4: Aspira Women's Health Director, Ellen O'Connor Vos, Reports Stock Transactions
SEC Form 4
Director Ellen O'Connor Vos reports the vesting and conversion of restricted stock units into common stock of Aspira Women's Health Inc.
Summary
- On September 30, 2024, Ellen O'Connor Vos, a director of Aspira Women's Health Inc., reported the vesting of 5,313 restricted stock units (RSUs) which converted into common stock.
- These RSUs were part of a grant of 21,250 RSUs awarded on August 22, 2024, as previously reported.
- Following the transaction, Vos directly owns 58,052 shares of Aspira Women's Health Inc. common stock and 15,937 RSUs.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions, and it doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction affects the director's ownership stake in the company.
- The vesting of RSUs is part of the director's compensation package.
Key Dates
| Date | Description |
|---|---|
| 08/22/2024 | Reporting person was granted 21,250 RSUs |
| 09/30/2024 | 5,313 RSUs vested and converted into common stock |
| 10/03/2024 | Date of signature for the Form 4 filing |
Keywords
Aspira Women's Health Inc., Director, Ellen O'Connor Vos, Form 4, Restricted Stock Units, RSUs, Common Stock, Vesting, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.